TailorMed

AI assists a workflow platform rather than constituting it. The core product is a financial navigation system that centralizes roughly 6,000 assistance program resources, verifies benefits through a clearinghouse, calculates remaining deductible and cost exposure, and manages enrollment.

The AI layer is real but bounded: the company describes surfacing assistance programs using automation and AI, intelligently matching patients to opportunities, and an in context generative AI assistant built for navigators. A separate service arm explicitly combines AI, automation, and human expert teams. What is on offer is workflow software with AI matching, not an autonomous system.

TailorMed's Highlands Oncology case study describes 'automatic patient identification and program matching so opportunities are never missed', and the home page promises 'every barrier removed, every patient reached'. A claim that nothing is missed is a claim about what is absent, which no review can show: a navigator working a queue sees the matches the system returned, not the ones it did not. A buyer who believes it will not build the manual check that would find them, and this product's failures are already invisible by design.

The structure itself is partly described. Navigators work queues the platform builds, forms are pre filled from live record data, and signatures are captured digitally. But the Core page also says patients in need are identified automatically, eligibility is automated using real time data, and Express Enroll enrols patients into copay, free drug and support programs fully automatically through direct manufacturer integrations, and nothing published says where a navigator must review before a submission leaves.

The components are described in general terms and nothing is identified. The Core page describes automated eligibility from real time data, automated form filling from the record, Express Enroll and TeamMate AI, an in context generative AI assistant for navigators, but names no model and gives no account of how eligibility is computed or how matches are evaluated.

That gap carries weight because the failure mode is silent. A missed match means a patient does not receive assistance they qualified for, and nobody involved ever learns it happened: not the patient, who was never told the program existed, and not the navigator, who saw no result to question. A false negative in this system is invisible by construction, which makes a published recall figure the single most useful number the company could disclose. None exists.

The architecture is described and no model provider is named. The Core page describes automated eligibility from real time data, Auto PDF form filling from the record, Express Enroll through direct manufacturer integrations, and TeamMate AI, an in context generative AI assistant for navigators, without saying whose generative model it is or where it runs. The privacy notice names service providers only by category (hosting, storage, analytics, database management, security, email, CRM), and no subprocessor list is published.

The onward parties are the product rather than a side effect. Applications go to foundations, manufacturers and assistance programs, 100 or more manufacturer programs are integrated directly, and a manufacturer running an assistance program also has a commercial interest in who is taking its drug.

The company now publishes a lot of figures, all vendor reported. The home page reports $7.4 billion in assistance secured to date, 75 million patients supported and 335 million prescriptions processed, with segment case figures: $11 million secured across a two state health system after a $2 million pilot; $800 million in copay assistance collected for pharmacies across 846,000 patients; a 96.7 percent approval rate through Express Enroll with 60 percent less time to enrol and 35 percent less time to fill for manufacturers. The Complete page reports a 44 percent increase in program approvals and 49 percent fewer accounts receivable days on assistance claims. A named customer, Highlands Oncology Group, reports a 35 percent increase in patients assisted and $1.3 million in copay assistance claimed in a year, and 28 days to return on investment.

None carries a method, baseline or period beyond the one year Highlands window, and each measures assistance secured or revenue recovered rather than the outcome the product exists for: whether patients started and stayed on therapy.

The privacy notice covers patients whose data reaches TailorMed through its customers, and states general handling: encryption in transit and at rest, access limited to a small number of authorized staff under confidentiality commitments, retention for as long as needed to provide the services, and a security program said to comply with HIPAA and HITECH. On secondary use it answers in the permissive direction: information may be anonymized or de identified and then used internally and externally, including to improve the services and for research. Nothing says whether identifiable customer data trains or improves the matching or the TeamMate AI assistant, or whether a customer can decline secondary use.

The data combination is unusually sensitive, because eligibility needs treatment plans alongside financial circumstances and insurance status, pulled live from the record. And the product's purpose is onward disclosure: forms go to foundations, manufacturers and assistance programs, each with its own retention, none party to the health system's agreement with TailorMed.

A status is stated and supported by a privacy document that reaches patients. The privacy notice covers individuals whose information reaches TailorMed through its customers, hospitals and other healthcare entities, and says TailorMed maintains a security management program that complies with HIPAA and HITECH, with encryption in transit and at rest and access limited to a small number of authorized staff. It places responsibility for consents on the customer.

No business associate agreement or summary of its terms is published, and the notice does not use the words business associate. The contracting question is layered: the platform pulls live records from the health system and then submits patient information onward to foundations, manufacturers and assistance programs that are not parties to the health system's agreement. What governs the data once it leaves for a program application goes unaddressed, and that is where the covered entity's chain of obligations runs out.

TailorMed announced in April 2022 that it had completed a SOC 2 Type II examination by an independent assessor, naming the type, and the company has a named chief security officer. The privacy notice adds that its security management program complies with HIPAA and HITECH, with encryption in transit and at rest.

The examination was described as mapped to the HITRUST assessment, and mapping a SOC 2 to HITRUST criteria is not holding a HITRUST certification. A SOC 2 Type II report also covers a defined period and is renewed, so a 2022 announcement establishes that an examination happened, not that a current report exists. There is no trust center, so neither the current report nor its observation period is public, and nothing says which systems are in scope, including whether TeamMate AI and the manufacturer integrations are covered. The company's own phrasing, that the results suggest a compliant framework, is softer than a plain statement.

No FDA pathway applies. The platform operates on financial assistance, benefits and enrollment workflow with no clinical decision surface.

The compliance surface that does govern here is substantial, and the company publishes no position on it. Copay assistance and manufacturer program rules carry federal anti kickback and beneficiary inducement constraints that determine which patients may lawfully receive which forms of assistance, and those rules differ sharply between commercially insured and federally insured patients. A platform that automates matching and enrollment at scale is operating inside those constraints on every transaction. There is no account of how the eligibility logic encodes them or of who is accountable when a match is wrong.

Nothing on the home page, the Core and Complete solution pages or the privacy notice describes how the matching, prioritization or TeamMate AI assistant is evaluated, monitored or checked across patient groups, and no responsible AI statement is published.

The equity question here is direct. A system that finds and prioritizes patients by assistance opportunity is allocating a scarce navigator's time. If prioritization favors higher dollar opportunities, it may systematically underserve patients whose barrier is smaller in absolute terms but just as decisive to whether they start or stay on treatment: a few hundred dollars is the difference between filling a prescription and abandoning it for many people, and it will never rank above a five figure infusion in a queue sorted by recoverable value. Insurance type matters too, since manufacturer copay help is generally closed to Medicare and Medicaid patients and a system tuned on commercial copay recovery will look least at them.

Nothing published says what happens when the platform gets it wrong: no warranty, no remediation commitment and no error rate for identification, eligibility or matching. The failures here are unusually hard to see. A missed match means a patient never receives assistance they qualified for, and nobody learns it happened: the patient was never told the program existed and the navigator saw no result to question. A wrong eligibility call or a mis-filled form can mean a denied application, a delayed start of therapy, or assistance clawed back later. Express Enroll submits enrollments automatically through direct manufacturer integrations, so some of those errors leave the building without a navigator reading them.

The figures the company publishes are volumes secured, which say nothing about the share missed; a case study describes automatic identification and matching 'so opportunities are never missed', which no published figure supports.

Integration is claimed through standards and nothing is named. The Core page says the platform is deeply integrated with health system IT, keeps patient, prescription and program data in sync via HL7 and FHIR, the TailorMed API or SFTP, and populates program forms from live EHR data, and it verifies benefits through a clearinghouse. That is a real clinical data dependency, since the pharmacy module follows the treatment plan. But no record system, clearinghouse or production site is named anywhere on the site, so none of it can be checked.

The manufacturer side is better specified than the clinical one: Express Enroll runs through direct integrations with pharmaceutical support programs.

Residency is stated. The privacy notice, which covers patients whose data reaches TailorMed through its customers, says information is stored exclusively in the United States and may be processed in the United States and Israel, where the company is based. Hosting and storage are provided by service providers the notice names only by category.

What is left open is isolation. TailorMed describes itself as a national network connecting patients, providers, pharmacies and life sciences companies, with direct integrations into manufacturer programs, so data moves between participants by design; nothing says what stays inside one provider's instance, how customers are separated, or which processing happens in Israel.

No published pricing across any of the product lines.

The company monetizes on several sides at once: a care team platform sold to providers, a patient facing product, a tech enabled service arm, and separately digital solutions sold to life sciences companies to improve access and time to therapy across its network. A provider is buying from a company that is also selling to the manufacturers whose assistance programs the platform matches patients into.

There is a legitimate reading of that, since the same network effect is what makes the matching work at all. But the company does not disclose which manufacturer relationships exist alongside a given provider's deployment, or whether any of them influence the order in which programs are presented.

Broad across the medication access surface, spanning health systems, oncology practices, infusion centers, and pharmacies, with life sciences companies as a separate customer class. Functional coverage runs from identifying financially at risk patients through enrollment, free and replacement drug inventory management, and adherence support. Oncology and infusion are the evident center of gravity given the case studies and the treatment plan driven pharmacy workflow, which is where high cost specialty medications concentrate.